ANAVEX LIFE SCIENCES CORP.
AVXL evidence brief
What we can confirm
- Market Cap:
- $246.6M
What it means
What to watch
Prepared research question
What matters most for AVXL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AVXL
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing its lead oral SIGMA-1 receptor agonist, ANAVEX 2-73 (blarcamesine), for early Alzheimer's disease, Rett syndrome, and Fragile X syndrome, with a recent strategic shift under new leadership to prioritize FDA alignment and Phase 3 planning.
Key risk: Dependence on ANAVEX 2-73
Market Cap
$246.6M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 6 clinical trials for ANAVEX LIFE SCIENCES CORP..
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing its lead oral SIGMA-1 receptor agonist, ANAVEX 2-73 (blarcamesine), for early Alzheimer's disease, Rett syndrome, and Fragile X syndrome, with a recent strategic shift under new leadership to prioritize FDA alignment and Phase 3 planning.
- Lead compound ANAVEX 2-73 (blarcamesine) is an investigational oral SIGMA-1 receptor agonist being developed for early Alzheimer's disease, Rett syndrome, and Fragile X syndrome [sec_mda · as of 2026-08-28].
- Cash and equivalents were $118.3M as of 2026-06-30, with net income of $7.8M and shareholders' equity of $112.4M for the same period [sec].
- The company has de-prioritized other assets (ANAVEX 3-71, 1-41, 1066), pausing development work and making future work contingent on additional funding or a strategic partnership [sec_mda · as of 2026-08-28].
- Anavex has submitted completed Alzheimer's disease clinical study data and a Rett syndrome formal meeting request to the FDA, with an IND submission for Fragile X syndrome planned for September 2026 [news · published 2026-08-25].
- The company expects its cash runway to extend into mid to late fiscal 2028 [news · published 2026-08-25].
What works
- Cash position of $118.3M as of 2026-06-30 provides a runway into mid to late fiscal 2028, supporting ongoing clinical development without near-term financing pressure [news · published 2026-08-25].
- The company reported net income of $7.8M for the period ending 2026-06-30, indicating a period of profitability [sec].
- Management is actively engaging with the FDA to align on a clear regulatory and clinical development strategy, which could reduce development risk [sec_mda · as of 2026-08-28].
What to weigh
- The company has de-prioritized its other pipeline assets (ANAVEX 3-71, 1-41, 1066), pausing their development and making future progress dependent on external funding or partnerships [sec_mda · as of 2026-08-28].
- Anavex will require substantial additional capital to develop its ANAVEX 2-73 programs and fund operations for the foreseeable future, with expenses expected to increase [sec_mda · as of 2026-08-28].
- The company faces all risks incidental to pharmaceutical development, including potential unforeseen expenses, difficulties, complications, delays, and other unknown factors [sec_mda · as of 2026-08-28].
From the filings
Quoted directly from source documents.
Lead compound is an oral SIGMA-1 receptor agonist
“ANAVEX 2-73 (blarcamesine), an investigational oral SIGMA-1 receptor agonist”
SEC MD&A · August 28, 2026
De-prioritization of other assets
“we have de-prioritized our other assets, including ANAVEX ® 3-71, currently in the clinical stage, and ANAVEX ® 1-41 and ANAVEX ® 1066, currently in preclinical development”
SEC MD&A · August 28, 2026
Risks & what to watch (4)›
Key risks
- Dependence on ANAVEX 2-73 — The company's pipeline is heavily concentrated on a single lead compound, with all other assets de-prioritized [sec_mda · as of 2026-08-28].
- Need for additional capital — Substantial additional capital is required to fund ANAVEX 2-73 development and operations, with expenses expected to rise [sec_mda · as of 2026-08-28].
- Regulatory uncertainty — The FDA's view on past efficacy data and the path to approval for early Alzheimer's disease remains unclear [sec_mda · as of 2026-08-28].
- De-prioritized asset risk — Development of ANAVEX 3-71, 1-41, and 1066 is paused, with future work contingent on partnerships or funding [sec_mda · as of 2026-08-28].
What to watch
- FDA feedback on the submitted Alzheimer's disease clinical study data and the Rett syndrome formal meeting request [news · published 2026-08-25].
- IND submission for Fragile X syndrome, planned for September 2026 [news · published 2026-08-25].
- Any updates on the regulatory and clinical development strategy for ANAVEX 2-73 following FDA discussions [sec_mda · as of 2026-08-28].
- Potential strategic partnerships or funding for de-prioritized assets [sec_mda · as of 2026-08-28].
Sources: News · SEC filings · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run ANAVEX LIFE SCIENCES CORP. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ANAVEX LIFE SCIENCES CORP. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
187
Total value held
$118.8M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 7,609,618 | $23.4M |
| state street corp | 4,512,028 | $13.9M |
| vanguard capital management llc | 3,863,950 | $11.9M |
| two sigma investments, lp | 3,247,888 | $10.0M |
| geode capital management, llc | 2,188,275 | $6.7M |
| susquehanna international group, llp | 995,663 | $3.1M |
| summit financial, llc | 940,455 | $2.9M |
| bank of america corp /de/ | 863,150 | $2.6M |
| goldman sachs group inc | 804,435 | $2.5M |
| vanguard portfolio management llc | 783,148 | $2.4M |
Showing top 10 of 187 institutional holders of ANAVEX LIFE SCIENCES CORP.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 21.4%
- Days to cover
- 18.4
- Shares short
- 19,011,626
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AVXL short interestGovernance
Frequently asked questions
What is the AI investment thesis for ANAVEX LIFE SCIENCES CORP.?
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing its lead oral SIGMA-1 receptor agonist, ANAVEX 2-73 (blarcamesine), for early Alzheimer's disease, Rett syndrome, and Fragile X syndrome, with a recent strategic shift under new leadership to prioritize FDA alignment and Phase 3 planning.
Who is the CEO of ANAVEX LIFE SCIENCES CORP.?
Dr. Terrie Kellmeyer Ph.D. is the chief executive officer of ANAVEX LIFE SCIENCES CORP. (AVXL).
Where is ANAVEX LIFE SCIENCES CORP. headquartered?
ANAVEX LIFE SCIENCES CORP. (AVXL) is headquartered in New York, NY, United States.
What therapeutic areas does ANAVEX LIFE SCIENCES CORP. focus on?
ANAVEX LIFE SCIENCES CORP. develops therapies across Rare Disease, Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.